BACKGROUND: Long-term survival rates for patients with stage III-IV Hodgkin lymphoma, or advanced Hodgkin lymphoma (aHL), have increased substantially since the 1960s. Because large-scale research of aHL is rare, we aimed to demonstrate the differences in incidence and survival of aHL according to four patient variables in recent decades, with a focus on the outcomes of treatment of aHL and the advancement of public health care. MATERIALS AND METHODS: Data on aHL cases diagnosed during 1984-2013 were extracted from the Surveillance, Epidemiology, and End Results Program database. Relative survival, Kaplan-Meier, and Cox proportional hazards regression analyses were performed to identify prognosis indicators for aHL. RESULTS: The incidence r...
Population-based studies of classical Hodgkin lymphoma (cHL) in contemporary clinical practice are s...
Population-based studies of classical Hodgkin lymphoma (cHL) in contemporary clinical practice are s...
Introduction: During the last three decades, major advances have been made in the therapy of Hodgkin...
Background: The Nottinghamshire Lymphoma Registry contains the details of all the patients diagnose...
Objective To evaluate improvement in survival of lymphoma patients from 1990 to 2014, stratified by ...
Objective: To evaluate improvement in survival of lymphoma patients from 1990 to 2014, stratified by...
OBJECTIVE:To evaluate improvement in survival of lymphoma patients from 1990 to 2014, stratified by ...
BACKGROUND: The Nottinghamshire Lymphoma Registry contains the details of all the patients diagnosed...
Trends in Hodgkin lymphoma (HL) survival among patients treated outside of clinical trials provide r...
Background: Few studies have examined the impact of treatment-related morbidity on long-term, cause-...
Abstract Background: Survival from Hodgkin’s lymphoma (HL) increased during the last ...
Abstract Background: Hodgkin lymphoma (HL) is one of the most common, and one of the ...
Background: Hodgkin lymphoma (HL) is the paradigm of curable disease. This study analyzed the overal...
BackgroundPrevious studies documented racial/ethnic and socioeconomic disparities in survival after ...
Limited information is available from developing countries on long-term outcome of patients with Hod...
Population-based studies of classical Hodgkin lymphoma (cHL) in contemporary clinical practice are s...
Population-based studies of classical Hodgkin lymphoma (cHL) in contemporary clinical practice are s...
Introduction: During the last three decades, major advances have been made in the therapy of Hodgkin...
Background: The Nottinghamshire Lymphoma Registry contains the details of all the patients diagnose...
Objective To evaluate improvement in survival of lymphoma patients from 1990 to 2014, stratified by ...
Objective: To evaluate improvement in survival of lymphoma patients from 1990 to 2014, stratified by...
OBJECTIVE:To evaluate improvement in survival of lymphoma patients from 1990 to 2014, stratified by ...
BACKGROUND: The Nottinghamshire Lymphoma Registry contains the details of all the patients diagnosed...
Trends in Hodgkin lymphoma (HL) survival among patients treated outside of clinical trials provide r...
Background: Few studies have examined the impact of treatment-related morbidity on long-term, cause-...
Abstract Background: Survival from Hodgkin’s lymphoma (HL) increased during the last ...
Abstract Background: Hodgkin lymphoma (HL) is one of the most common, and one of the ...
Background: Hodgkin lymphoma (HL) is the paradigm of curable disease. This study analyzed the overal...
BackgroundPrevious studies documented racial/ethnic and socioeconomic disparities in survival after ...
Limited information is available from developing countries on long-term outcome of patients with Hod...
Population-based studies of classical Hodgkin lymphoma (cHL) in contemporary clinical practice are s...
Population-based studies of classical Hodgkin lymphoma (cHL) in contemporary clinical practice are s...
Introduction: During the last three decades, major advances have been made in the therapy of Hodgkin...